Obesity and kidney protection

Journal of Nephropathology

Volumn 3, Issue 3, 2014, Pages 91-97

  Chandra, Aravind ^a   Biersmith, Michael ^a   Tolouian, Ramin ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Fat; Metabolic syndrome; Renal disease

Indexed keywords

EID: 84925183130     PISSN: 22518363     EISSN: 22518819     Source Type: Journal    
DOI: 10.12860/jnp.2014.18     Document Type: Review

References (52)

1. Bate J. A new and literal translation, from the Hebrew, of the Pentateuch of Moses, and of the historical books of the Old Testament, to the end of the second book of Kings: with notes critical and explanatory. Printed for W. Faden, B. Law, 1773.
2. Eknoyan G. The kidneys in the Bible: what happened? J Am Soc Nephrol 2005;16(12):3464-71.
3. Ogden C, Carroll M, Kit B, Flegal K. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief 2012;82:1-8.
4. CDC VitalSigns - Adult Obesity. (n.d.). Retrieved March 6, 2014, from http://www.cdc.gov/VitalSigns/adultobesity/
5. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev 2012;70(1):3–21.
6. Gupta N, Goel K, Shah P, Misra A. Childhood obesity in developing countries: epidemiology, determinants, and prevention. Endocr Rev 2012; 33(1):48–70.
7. Muennig P, Lubetkin E, Jia H, Franks P. Gender and the Burden of Disease Attributable to Obesity. Am J Public Health 2006;96(9):1662-8.
8. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288(21):2709-16.
9. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004;140(3):167-74.
10. Abrass CK. Overview: obesity: what does it have to do with kidney disease? J Am Soc Nephrol 2004; 15(11):2768-72.
11. Palatini P. Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant 2012;27(5):1708-14.
12. Wuerzner G, Pruijm M, Maillard M, Bovet P, Renaud C, Burnier M, et al. Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population. Am J Kidney Dis 2012;56(2):303-12.
13. Zoccali C. Overweight, obesity and metabolic alterations in chronic kidney disease. Prilozi 2009;30(2):17-31.
14. Tomaszewski M, Charchar FJ, Maric C, McClure J, Crawford L, Grzeszczak W, et al. Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int 2007; 71(8):816-21. doi:10.1038/sj.ki.5002160
15. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003;14(6):1480-6.
16. Li Z, Woollard JR, Wang S, Korsmo MJ, Ebrahimi B, Grande JP, et al. Increased glomerular filtration rate in early metabolic syndrome is associated with renal adiposity and microvascular proliferation. Am J Physiol Renal Physiol 2011; 301(5):F1078–87.
17. Chalmers L, Kaskel FJ, Bamgbola O. The role of obesity and its bioclinical correlates in the progression of chronic kidney disease. Adv Chronic Kidney Dis 2006;13(4):352-64.
18. Schmieder RE, Veelken R, Schobel H, Dominiak P, Mann JF, Luft FC. Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension. J Am Soc Nephrol 1997;8:893-900
19. Palatini P, Mormino P, Dorigatti F, Santonastaso M, Mos L, De Toni R, et al. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertension: the HARVEST. Kidney Int 2006;70:578-84.
20. Okada R, Yasuda Y, Tsushita K, Wakai K, Hamajima N, Matsuo S. Glomerular hyperfiltration in prediabetes and prehypertension. Nephrol Dial Transplant 2012;27(5):1821-5.
21. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eighth joint national committee (jnc 8). JAMA;311(5):507-20.
22. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000;57(5):1803-17.
23. Vaziri ND, Bai Y, Ni Z, Quiroz Y, Pandian R, Rodriguez- Iturbe B. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J Pharmacol Exp Ther 2007; 323(1);85-93.
24. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77(6):1993-2000.
25. Kuwabara A, Satoh M, Tomita N, Sasaki T, Kashihara N. Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats. Diabetologia 2010;53(9):2056-65.
26. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9.
27. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-60.
28. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311):1004-10.
29. Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106(6):672-8.
30. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36(3):646-61.
31. Zoccali C, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011; 22(10):1923-30.
32. Melsom T, Mathisen UD, Ingebretsen OC, Jenssen TG, Njølstad I, Solbu MD, et al. Impaired fasting glucose is associated with renal hyperfiltration in the general population. Diabetes Care 2011; 34(7):1546-51.
33. Mänttäri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995;26(4):670–675.
34. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14(8):2084-91.
35. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentrerandomised placebo-controlled trial. Lancet 2004; 364(9435):685-96.
36. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentrerandomised controlled trial. Lancet 2003; 361(9364):1149-158.
37. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57(7):728-34.
38. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kid Dis 2003; 41(3):565-70.
39. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim, SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. J Am Soc Nephrol 2002;39(6):1213-7.
40. Ikejiri A, Hirano T, Murayama S, Yoshino G, Gushiken N, Hyodo T, et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 2004;53(9):1113-7.
41. Van den Akker JM, Bredie SJH, Diepenveen SHA, van Tits LJH, Stalenhoef AFH, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 2003;16(2):238-44.
42. Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353(3): 238–248.
43. Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498–1509.
44. Palla R, Panichi V, Finato V, Parrini M Andreini B, Bianchi AM, et al. Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 1994; 14(1): 35–43.
45. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870-8.
46. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; 70(12):2116-23.
47. Skøtt P, Hommel E, Bruun NE, Arnold-Larsen S, Parving HH. Effects of acetazolamide on kidney function in type 1 (insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 1998; 31(11): 806–810.
48. Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration. June 16, 2010. On-going trial http://clinicaltrials.gov/ct2/show/ NCT01146288
49. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr 1998;68(4):899-917.
50. Mallamaci F, Leonardis D, Bellizzi V, Zoccali C. Does high salt intake cause hyperfiltration in patients with essential hypertension? J Hum Hypertens 1996;10:157-161.
51. Campese VM, Parise M, Karubian F, Bigazzi R. Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension 1991; 18(6):805-12.
52. Svetkey LP, Sacks FM, Obarzanek E, Vollmer WM, Appel LJ, Lin PH. The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): rationale and design. DASH-Sodium Collaborative Research Group. J Am Diet Assoc 1999; 99(8 Suppl), S96–104.